Skip to main content

Table 3 Relationship between the expression of AR, MMPs and TIMPs by each cellular type in breast cancer.

From: Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

Factor

N

AR score values median (range)

p value

MMP-1

   

TC (-) vs. (+)

7/104

0(0–70)/80(0–288)

0.004

FC (-) vs. (+)

14/97

2.5(0–225)/80(0–288)

0.03

MIC (-) vs. (+)

30/81

53(0–225)/81(0–288)

n.s.

MMP-2

   

TC (-) vs. (+)

70/41

59.5(0–279)/90(0–288)

n.s.

FC (-) vs. (+)

83/28

69(0–288)/88(0–270)

n.s.

MIC (-) vs. (+)

108/3

68.5(0–288)/66(0–132)

n.s.

MMP-7

   

TC (-) vs. (+)

8/103

0(0–156)/80(0–288)

0.01

FC (-) vs. (+)

27/84

68(0–267)/74.5(0–288)

n.s.

MIC (-) vs. (+)

50/61

66(0–267)/81(0–288)

n.s.

MMP-9

   

TC (-) vs. (+)

27/84

48(0–270)/80.5(0–288)

n.s.

FC (-) vs. (+)

93/18

68(0–288)/83.5(0–270)

n.s.

MIC (-) vs. (+)

98/13

80(0–279)/30(0–288)

n.s.

MMP-11

   

TC (-) vs. (+)

11/100

8(0–168)/80(0–288)

0.03

FC (-) vs. (+)

33/78

53(0–264)/81(0–288)

n.s.

MIC (-) vs. (+)

72/39

68(0–270)/87(0–288)

n.s.

MMP-13

   

TC (-) vs. (+)

29/82

48(0–225)/74.5(0–288)

n.s.

FC (-) vs. (+)

54/57

56(0–267)/81(0–288)

n.s.

MIC (-) vs. (+)

70/41

64.5(0–279)/92(0–288)

n.s.

MMP-14

   

TC (-) vs. (+)

10/101

64.5(0–273)/69(0–288)

n.s.

FC (-) vs. (+)

21/90

92(0–273)/66.5(0–288)

n.s.

MIC (-) vs. (+)

50/61

64.5(0–273)/81(0–288)

n.s.

TIMP-1

   

TC (-) vs. (+)

6/105

0(0–225)/72(0–288)

n.s.

FC (-) vs. (+)

56/55

70(0–288)/69(0–273)

n.s.

MIC (-) vs. (+)

81/30

64(0–279)/96(0–288)

n.s.

TIMP-2

   

TC (-) vs. (+)

13/98

0(0–174)/80(0–288)

0.01

FC (-) vs. (+)

59/52

80(0–270)/63(0–288)

n.s.

MIC (-) vs. (+)

63/48

80(0–288)/68.5(0–279)

n.s.

TIMP-3

   

TC (-) vs. (+)

15/96

48(0–210)/76(0–288)

n.s.

FC (-) vs. (+)

42/69

50.5(0–225)/88(0–288)

n.s.

MIC (-) vs. (+)

53/58

64(0–279)/87(0–288)

n.s.